Comprehensive review identifies nine therapeutic peptides targeting metabolic, telomere, tissue, and neuroprotective aspects of healthy aging
Background
The global demographic shift towards an aging population necessitates interventions that extend healthspan and address age-related conditions. Fundamental hallmarks of aging, such as metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline, are key targets. Current standard-of-care often manages symptoms rather than underlying mechanisms. Therapeutic peptides offer a promising frontier, providing targeted, specific interventions by modulating various biological pathways and receptors, making them attractive candidates for gerontological medicine.
Study Design
Researchers conducted a comprehensive narrative review, systematically searching PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026. Key search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names like tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, and bremelanotide. A total of 20 primary sources were selected based on relevance, methodological quality, and their contribution to understanding peptide mechanisms and clinical outcomes in aging populations.
Results
The review identified nine therapeutic peptides spanning diverse interventions for aging. These included tirzepatide for metabolic restoration, epitalon for telomere biology, GHK-Cu for dermal regeneration, BPC-157 and TB-500 for tissue repair, Semax for neuroprotection, CJC-1295 and ipamorelin for growth hormone modulation, and bremelanotide for sexual function. FDA-approved agents, such as tirzepatide, demonstrated robust safety profiles derived from large-scale clinical trials. Conversely, non-approved peptides, while showing promising preclinical and limited clinical evidence, were noted to lack long-term safety data and systematic validation. This highlights a significant disparity in the evidence base. > Significant knowledge gaps remain regarding optimal dosing regimens, the effects of combination therapies, and reliable biomarkers for monitoring efficacy across these diverse peptide interventions.
Key Findings
- Nine therapeutic peptides identified for diverse healthy aging interventions.
- Tirzepatide targets metabolic restoration.
- Epitalon influences telomere biology.
- BPC-157 and TB-500 support tissue repair.
- Semax provides neuroprotection.
- CJC-1295 and ipamorelin modulate growth hormone.
Why It Matters
This comprehensive review consolidates the current understanding of therapeutic peptides in gerontology, offering a valuable resource for clinicians, researchers, and biohackers. It provides a clearer landscape of both evidence-backed and emerging peptide therapies for age-related concerns, guiding potential applications and future research directions. For peptide users, it underscores the importance of distinguishing between FDA-approved agents with established safety and non-approved compounds that, despite promising preclinical data, require more rigorous long-term safety and efficacy validation. The identified knowledge gaps emphasize the need for further studies to optimize dosing, explore synergistic combinations, and establish reliable biomarkers for personalized anti-aging protocols.
